USAResearch and clinical trials
In tuberous sclerosis, a drug given before seizures begin made no difference in development or autism
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
In the USA, early treatment with vigabatrin was tested in babies with tuberous sclerosis. The aim was to prevent developmental delay and autism. The study included 84 babies, and 65 were followed until age 3. There was no difference between the groups in development or autism. None of the children without seizures developed autism.
What does it mean for patients and families?
Early medication did not show the expected benefit in this study. Close monitoring of babies for seizures and development remains important. Decisions are made with a pediatric neurologist.
Source
PubMed (Pediatric Neurology): Neurodevelopmental Outcomes From the PREVeNT Trial.
Scientific paper: Neurodevelopmental Outcomes From the PREVeNT Trial. Pediatric Neurology, 2025. DOI: 10.1016/j.pediatrneurol.2025.09.006 · PubMed 41061327
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Tuberous sclerosis complex (TSC)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.